Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 11/20 | 1.00 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.39 |
| ▸ | ADRB3 | P13945 | 4/20 | 0.39 |
| ▸ | FSHR | P23945 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14697580 | 0.97 | CYP1A1 (1.00) | CYP1A1S1PR1ADRB2ADRB1ADRB3 | |
| SCHEMBL14119611 | 0.93 | CYP1A1 (1.00) | CYP1A1S1PR1 | |
| SCHEMBL14708665 | 0.90 | CYP1A1 (0.82) | CYP1A1S1PR1ADRB2ADRB1ADRB3 | |
| SCHEMBL16178130 | 0.90 | CYP1A1 (1.00) | CYP1A1S1PR1ADRB2ADRB1ADRB3 | |
| SCHEMBL16186806 | 0.87 | CYP1A1 (0.89) | CYP1A1 | |
| SCHEMBL16178146 | 0.87 | CYP1A1 (0.82) | CYP1A1S1PR1ADRB2ADRB1ADRB3 | |
| SCHEMBL16178229 | 0.87 | CYP1A1 (0.82) | CYP1A1S1PR1 | |
| SCHEMBL16178253 | 0.87 | CYP1A1 (1.00) | CYP1A1S1PR1ADRB2ADRB1ADRB3 | |
| SCHEMBL16186812 | 0.85 | CYP1A1 (0.90) | CYP1A1S1PR1ADRB2ADRB1ADRB3 | |
| SCHEMBL16178206 | 0.85 | CYP1A1 (0.86) | CYP1A1S1PR1ADRB2ADRB1ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9579306-B2 | Substituted 2-imidazolidinones and 2-imidazolones and their use in the treatment of cancer | UNIVERSITE LAVAL (CA) | 2017-02-28 | — | — | US | disclosed |
| US-9579306-B2 | Substituted 2-imidazolidinones and 2-imidazolones and their use in the treatment of cancer | UNIVERSITE LAVAL (CA) | 2017-02-28 | — | — | US | disclosed |
| US-9579306-B2 | Substituted 2-imidazolidinones and 2-imidazolones and their use in the treatment of cancer | UNIVERSITE LAVAL (CA) | 2017-02-28 | — | — | US | disclosed |
| US-20160184270-A1 | SUBSTITUTED 2-IMIDAZOLIDINONES AND 2-IMIDAZOLONES AND THEIR USE IN THE TREATMENT OF CANCER | UNIVERSITé LAVAL (CA) | 2016-06-30 | — | — | US | disclosed |
| US-20160184270-A1 | SUBSTITUTED 2-IMIDAZOLIDINONES AND 2-IMIDAZOLONES AND THEIR USE IN THE TREATMENT OF CANCER | UNIVERSITé LAVAL (CA) | 2016-06-30 | — | — | US | disclosed |
| US-20160184270-A1 | SUBSTITUTED 2-IMIDAZOLIDINONES AND 2-IMIDAZOLONES AND THEIR USE IN THE TREATMENT OF CANCER | UNIVERSITé LAVAL (CA) | 2016-06-30 | — | — | US | disclosed |
| US-9278937-B2 | Substituted 2-imidazolidinones and 2-imidazolones and their use in the treatment of cancer | UNIVERSITE LAVAL (CA) | 2016-03-08 | — | — | US | disclosed |
| US-9278937-B2 | Substituted 2-imidazolidinones and 2-imidazolones and their use in the treatment of cancer | UNIVERSITE LAVAL (CA) | 2016-03-08 | — | — | US | disclosed |
| US-9278937-B2 | Substituted 2-imidazolidinones and 2-imidazolones and their use in the treatment of cancer | UNIVERSITE LAVAL (CA) | 2016-03-08 | — | — | US | disclosed |
| US-20140315968-A1 | Substituted 2-Imidazolidinones and 2-Imidazolones and Their Use in the Treatment of Cancer | UNIVERSITE LAVAL (CA) | 2014-10-23 | — | — | US | disclosed |
| US-20140315968-A1 | Substituted 2-Imidazolidinones and 2-Imidazolones and Their Use in the Treatment of Cancer | UNIVERSITE LAVAL (CA) | 2014-10-23 | — | — | US | disclosed |
| US-20140315968-A1 | Substituted 2-Imidazolidinones and 2-Imidazolones and Their Use in the Treatment of Cancer | UNIVERSITE LAVAL (CA) | 2014-10-23 | — | — | US | disclosed |
| EP-2744786-A1 | SUBSTITUTED 2-IMIDAZOLIDINONES AND 2-IMIDAZOLONES AND THEIR USE IN THE TREATMENT OF CANCER | Université Laval (CA) | 2014-06-25 | — | — | EP | disclosed |
| WO-2013023274-A1 | SUBSTITUTED 2-IMIDAZOLIDINONES AND 2-IMIDAZOLONES AND THEIR USE IN THE TREATMENT OF CANCER | UNIVERSITE LAVAL (CA) | 2013-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160184270-A1 | SUBSTITUTED 2-IMIDAZOLIDINONES AND 2-IMIDAZOLONES AND THEIR USE IN THE TREATMENT OF CANCER | BRCA1, PRMT1, ARG1 | CYP1A1 908/4885S1PR1 2950/4885ADRB2 1862/4885 |
| US-20140315968-A1 | Substituted 2-Imidazolidinones and 2-Imidazolones and Their Use in the Treatment of Cancer | BRCA1, PRMT1, ARG1 | CYP1A1 908/4885S1PR1 2950/4885ADRB2 1862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.